Epidemiology of community-acquired pneumonia caused by S treptococcus pneumoniae in older adults: a narrative review

Curr Opin Infect Dis. 2024 Apr 1;37(2):144-153. doi: 10.1097/QCO.0000000000001005. Epub 2024 Feb 5.

Abstract

Purpose of review: This review covers updated perspectives on different aspects of pneumococcal community-acquired pneumonia (pCAP), including the epidemiology, clinical presentation, risk factors, antibiotic treatment, and existing preventive strategies in older adults.

Recent findings: pCAP remains the most prevalent condition among lower respiratory tract infections in the older adults according to Global Burden of Diseases 2019. Older adults can display atypical symptoms such as confusion, general clinical deterioration, new onset of and exacerbation of underlying illness that might trigger clinical suspicion of pCAP. Older adults with pCAP often experience increased disease severity and a higher risk of pulmonary complications compared with younger individuals, owing to age-related changes in immunity and a higher prevalence of comorbidities. Vaccination stands fundamental for prevention, emphasizing the need for effective immunization strategies, specifically tailored for older adults. There is a pressing need to reinforce efforts aimed at boosting pneumococcal vaccination rates.

Summary: Despite a high morbidity and mortality, the burden of pCAP, in particular hospital admission and occurrence of invasive infections, among the elderly population is not sufficiently documented. This review findings emphasize the substantial burden of pCAP in this vulnerable population, driven by factors such as advancing age and underlying comorbidities. The emergence of antibiotic-resistant pneumococcal strains further complicates treatment decisions and highlights the importance of tailored approaches for managing pCAP in older adults.

Publication types

  • Review

MeSH terms

  • Aged
  • Community-Acquired Infections* / epidemiology
  • Community-Acquired Infections* / prevention & control
  • Comorbidity
  • Hospitalization
  • Humans
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines
  • Pneumonia, Pneumococcal* / epidemiology
  • Pneumonia, Pneumococcal* / prevention & control
  • Respiratory Tract Infections* / epidemiology
  • Streptococcus pneumoniae

Substances

  • Pneumococcal Vaccines